HPGC Renmintongtai Pharmaceutical Corporation Stock price

Equities

600829

CNE000000G05

Pharmaceuticals

End-of-day quote Shanghai S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
6.57 CNY 0.00% Intraday chart for HPGC Renmintongtai Pharmaceutical Corporation -4.64% -15.98%
Sales 2022 9.64B 1.34B Sales 2023 10.39B 1.44B Capitalization 4.53B 628M
Net income 2022 263M 36.43M Net income 2023 292M 40.45M EV / Sales 2022 0.39 x
Net Debt 2022 86.9M 12.04M Net cash position 2023 295M 40.89M EV / Sales 2023 0.41 x
P/E ratio 2022
14 x
P/E ratio 2023
15.5 x
Employees 3,030
Yield 2022 *
-
Yield 2023
-
Free-Float 24.93%
More Fundamentals * Assessed data
Dynamic Chart
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
HPGC Renmintongtai Chairman Steps Down; Successor Named MT
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Half Year Ended June 30, 2022 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
HPGC Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Hpgc Renmintongtai Pharmaceutical Corporation Reports Earnings Results for the Half Year Ended June 30, 2020 CI
More news
1 week-4.64%
Current month+4.62%
1 month+7.70%
3 months-14.23%
6 months-16.41%
Current year-15.98%
More quotes
1 week
6.40
Extreme 6.4
6.85
1 month
6.17
Extreme 6.17
6.93
Current year
4.96
Extreme 4.96
8.45
1 year
4.96
Extreme 4.96
10.50
3 years
4.96
Extreme 4.96
10.50
5 years
4.96
Extreme 4.96
11.50
10 years
4.88
Extreme 4.88
29.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 -
Director of Finance/CFO 52 22-04-06
Chief Administrative Officer 50 -
Members of the board TitleAgeSince
Chairman 52 -
Director/Board Member 61 -
Chief Executive Officer 55 -
More insiders
Date Price Change Volume
24-03-28 6.57 0.00% 8,054,425
24-03-27 6.57 -0.76% 4,895,300
24-03-26 6.62 -0.30% 4,086,909
24-03-25 6.64 -2.21% 4,802,881
24-03-22 6.79 -1.45% 5,530,300

End-of-day quote Shanghai S.E., March 27, 2024

More quotes
HPGC Renmintongtai Pharmaceutical Corporation, formerly Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd., is a China-based company, principally engaged in the wholesale and retail of pharmaceuticals. The Company principally engages in the sales of Chinese medicines and western drugs. It also engages in the sales of medical equipment, healthcare products, daily necessities, glass apparatus, chemical, among others. The Company distributes its products mainly within domestic markets.
More about the company
  1. Stock
  2. Equities
  3. Stock HPGC Renmintongtai Pharmaceutical Corporation - Shanghai S.E.